Autifony Therapeutics Limited

Glaxo Group Limited

Smithkline Beecham Corporation

Glaxosmithkline LLC

Convergence Pharmaceuticals Limited

Nerre Therapeutics Limited

Glaxo Wellcome Manufacturing Pte Ltd

Smithkline Beecham Croporation

Autifony Therapeuctics Limited

Giuseppe Alvaro

Agostino Marasco

Charles Large

Riccardo Giovannini

Romano Di Fabio

Dieter Hamprecht

Anne Decor

Paolo Dambruoso

Simona Tommasi

Yves St-Denis

Antonella Ursini

Markus Bergauer

Giuseppe Guercio

Sandro Belvedere

Maria Elvira Tranquillini

Roberto Profeta

Stefano Fontana

David Amantini

Anne Dècor

Simone Spada

Marsia Tampieri

Emiliano Castiglioni

Francesca Bonetti

Daniele Andreotti

Alessandro Falchi

Paolo Maragni

Mauro Corsi

Alfredo Paio

Romano DiFabio

Alessandro Pontiroli

Torquil I M Jack

Sergio Melotto

Francesca Pavone

Guido Marconi

Paola Maragni

Anne Décor

Damiano Ghirlanda

The disclosure provides compounds of formula (I): said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

Hydantoin derivatives useful as Kv3 inhibitors

The invention provides compounds of formula (I):  Said compounds being modulators of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

Compounds

Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders. 

Triazoles as Kv3 inhibitors

The present invention provides a modulator of Kv3.1 and/or Kv3.2 and/or Kv3.3 channels for use in the prophylaxis or treatment of pain. Modulators for use in the prophylaxis or treatment of pain include compounds of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof and/or derivative thereof: (I). 

Modulators of KV3 channels to treat pain

The present invention provides compounds of the formula (I) and their use as Kv3 modulators. 

The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.

Imidazolidinedione derivatives

The invention provides compounds of formula (I): Said compounds being modulators of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

Triazoles as KV3 inhibitors

Methods for the treatment of Fragile X that includes administering to a subject in need thereof a compound of formula (I): are described herein.

Growing community of inventors

Verona, Italy

Giuseppe Alvaro